Seattle Genetics (SGEN) 31.57 $SGEN
Look for Shares of Seattle Genetics to Potentially Rebound after Yesterday's 4.35% Sell Off
Comtex SmarTrend(R) - Wed Feb 11, 4:40PM CST
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $30.13 to a high of $32.30. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $32.19 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SGEN: 31.57 (+0.36)
Seattle Genetics Posts Narrower-than-Expected Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:18AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 22 cents per share, narrower than the Zacks Consensus Estimate of a loss of 27 cents.
BMRN: 100.76 (+1.98), SGEN: 31.57 (+0.36), BMY: 60.04 (+0.56)
Seattle Genetics updates guidance after Q4 results
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 6:49AM CST
SGEN: 31.57 (+0.36)
Seattle Genetics' (SGEN) CEO Clay Siegall on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 9:08PM CST
SGEN: 31.57 (+0.36)
Seattle Genetics, Inc. Exceeds Expecations
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 6:42PM CST
Seattle Genetics rounded out 2014 with revenue a hair above the guidance it gave last quarter. For the year, the biotech registered $178.2 million in sales of its blood cancer drug Adcetris in the U.S. and Canada, just above the $177 million upper...
SGEN: 31.57 (+0.36), BMY: 60.04 (+0.56)
Seattle Genetics reports 4Q loss
Automated Insights - Tue Feb 10, 4:11PM CST
BOTHELL, Wash. (AP) _ Seattle Genetics Inc. (SGEN) on Tuesday reported a loss of $26.7 million in its fourth quarter.
SGEN: 31.57 (+0.36)
Seattle Genetics (SGEN) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 10, 3:25PM CST
SGEN: 31.57 (+0.36)
Seattle Genetics beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:07PM CST
SGEN: 31.57 (+0.36)
Seattle Genetics Reports Fourth Quarter and Year 2014 Financial Results
Business Wire - Tue Feb 10, 3:02PM CST
---Phase 3 AETHERA Supplemental BLA Submission Planned in First Quarter 2015-
SGEN: 31.57 (+0.36)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:35PM CST
SGMO: 15.40 (+0.14), USNA: 101.37 (+0.53), RLOC: 3.58 (+0.42), ATEN: 4.14 (-0.09), VSAT: 62.71 (+0.53), RPXC: 13.94 (+0.42), TRMB: 26.86 (-0.40), KGC: 2.81 (-0.17), WSH: 47.83 (-0.55), TSRA: 39.27 (-0.05), FTI: 41.05 (+1.26), ACGL: 59.95 (+0.36), LOCK: 14.10 (-0.19), CERN: 70.98 (+1.15), CAP: 24.72 (-0.61), JIVE: 5.34 (+0.02), WU: 19.02 (+0.71), AKAM: 68.77 (+1.18), SKT: 36.80 (-0.21), NCR: 28.71 (+0.21), FRT: 143.96 (-0.58), SCI: 24.76 (+0.02), ELON: 1.16 (-0.01), GNW: 8.67 (+0.17), RKUS: 10.53 (-0.12), GHDX: 31.12 (+0.28), BLKB: 44.45 (+0.50), PXD: 157.85 (+9.71), SGEN: 31.57 (+0.36), OHI: 40.61 (-0.06), THOR: 40.01 (+0.54), MKTO: 28.24 (+0.20), CRL: 73.61 (-0.33), TMH: 59.69 (-0.19), ANDE: 45.11 (+0.71), XOOM: 15.77 (+0.64), HIW: 46.66 (-0.68), PAYC: 32.37 (-0.71)
Which Biotech Stock Should Pfizer, Inc. Buy?
Motley Fool Staff, Brian Orelli, Leo Sun, and George Budwell - Motley Fool - Sun Feb 08, 7:02AM CST
Source: Pfizer. Pfizer is struggling to offset slowing sales tied to expiring patents, and that has some observers thinking that Pfizer remains on the hunt to buy another drugmaker that can spark its growth. Earlier this week, Pfizer announced...
BIIB: 391.66 (-0.45), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), CLDN: 16.45 (-0.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), SGEN: 31.57 (+0.36), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
Seattle Genetics to Present at Leerink Global Healthcare Conference
Business Wire - Thu Feb 05, 8:01AM CST
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the Leerink Global Healthcare Conference on Thursday, February 12, at 11:35 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics' website at www.seattlegenetics.com in the Investors and News section.
SGEN: 31.57 (+0.36)
Earnings Peek: Market Seems Determined To Keep Seattle Genetics In The $30s
Clinically Sound Investor - at Seeking Alpha - Mon Jan 26, 12:20PM CST
SGEN: 31.57 (+0.36)
Seattle Genetics reports February 10
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 8:45AM CST
SGEN: 31.57 (+0.36)
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2014 Financial Results on February 10, 2015
Business Wire - Wed Jan 21, 8:01AM CST
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its fourth quarter and year 2014 financial results on Tuesday, February 10, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
SGEN: 31.57 (+0.36)
ALPS Puts Twist On Biotech Investing With Medical Breakthrough ETF
Zacks Funds - Seeking Alpha - Wed Jan 14, 11:48PM CST
Health & Biotech Equities ETFs had an astounding 2014 with the NASDAQ Biotechnology index returning a stellar 34% in 2014 - emerging as the biggest winner among all the sectors. Despite overall valuation concerns in the early phase of the year,...
BBP: 28.36 (+0.12), SBIO: 27.28 (+0.14), BBC: 28.98 (+0.18), SGEN: 31.57 (+0.36), IBB: 323.46 (+3.04), RCPT: 115.83 (-0.66), NPSP: 45.88 (+0.03), XLV: 70.72 (+0.28)
Eli Lilly Inks Oncology Deals with Merck, Bristol-Myers - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 4:35PM CST
Eli Lilly and Company (LLY) has entered into separate agreements with Merck and Bristol-Myers Squibb Company to evaluate its drugs for several oncology indications.
AGN: 229.49 (+1.87), SGEN: 31.57 (+0.36), MRK: 58.81 (-0.07), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56)
Seattle Genetics, Bristol-Myers to Study Adcetris-Opdivo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 4:46PM CST
Seattle Genetics, Inc. (SGEN) and partner Bristol-Myers Squibb Company inked a deal to develop an investigational combination of Adcetris and Opdivo.
BIIB: 391.66 (-0.45), SGEN: 31.57 (+0.36), ALXN: 182.29 (+6.02), BMY: 60.04 (+0.56)
Seattle Genetics and Bristol-Myers team up in blood cancer trials
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 12:44PM CST
SGEN: 31.57 (+0.36), BMY: 60.04 (+0.56)
Bristol-Myers' stock jumps on lung-cancer drug success
By The Associated Press - AP - Mon Jan 12, 10:05AM CST
Better patient survival rates prompted Bristol-Myers Squibb to bring an early end to an advanced study of a potential treatment for one of the most common forms of lung cancer.
SGEN: 31.57 (+0.36), BMY: 60.04 (+0.56)
Look for Shares of Seattle Genetics to Potentially Rebound after Yesterday's 4.35% Sell Off
Comtex SmarTrend(R) - Wed Feb 11, 4:40PM CST
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $30.13 to a high of $32.30. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $32.19 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SGEN: 31.57 (+0.36)
Seattle Genetics Posts Narrower-than-Expected Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:18AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 22 cents per share, narrower than the Zacks Consensus Estimate of a loss of 27 cents.
BMRN: 100.76 (+1.98), SGEN: 31.57 (+0.36), BMY: 60.04 (+0.56)
Seattle Genetics updates guidance after Q4 results
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 6:49AM CST
SGEN: 31.57 (+0.36)
Seattle Genetics' (SGEN) CEO Clay Siegall on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 9:08PM CST
SGEN: 31.57 (+0.36)
Seattle Genetics, Inc. Exceeds Expecations
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 6:42PM CST
Seattle Genetics rounded out 2014 with revenue a hair above the guidance it gave last quarter. For the year, the biotech registered $178.2 million in sales of its blood cancer drug Adcetris in the U.S. and Canada, just above the $177 million upper...
SGEN: 31.57 (+0.36), BMY: 60.04 (+0.56)
Seattle Genetics reports 4Q loss
Automated Insights - Tue Feb 10, 4:11PM CST
BOTHELL, Wash. (AP) _ Seattle Genetics Inc. (SGEN) on Tuesday reported a loss of $26.7 million in its fourth quarter.
SGEN: 31.57 (+0.36)
Seattle Genetics (SGEN) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 10, 3:25PM CST
SGEN: 31.57 (+0.36)
Seattle Genetics beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:07PM CST
SGEN: 31.57 (+0.36)
Seattle Genetics Reports Fourth Quarter and Year 2014 Financial Results
Business Wire - Tue Feb 10, 3:02PM CST
---Phase 3 AETHERA Supplemental BLA Submission Planned in First Quarter 2015-
SGEN: 31.57 (+0.36)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:35PM CST
SGMO: 15.40 (+0.14), USNA: 101.37 (+0.53), RLOC: 3.58 (+0.42), ATEN: 4.14 (-0.09), VSAT: 62.71 (+0.53), RPXC: 13.94 (+0.42), TRMB: 26.86 (-0.40), KGC: 2.81 (-0.17), WSH: 47.83 (-0.55), TSRA: 39.27 (-0.05), FTI: 41.05 (+1.26), ACGL: 59.95 (+0.36), LOCK: 14.10 (-0.19), CERN: 70.98 (+1.15), CAP: 24.72 (-0.61), JIVE: 5.34 (+0.02), WU: 19.02 (+0.71), AKAM: 68.77 (+1.18), SKT: 36.80 (-0.21), NCR: 28.71 (+0.21), FRT: 143.96 (-0.58), SCI: 24.76 (+0.02), ELON: 1.16 (-0.01), GNW: 8.67 (+0.17), RKUS: 10.53 (-0.12), GHDX: 31.12 (+0.28), BLKB: 44.45 (+0.50), PXD: 157.85 (+9.71), SGEN: 31.57 (+0.36), OHI: 40.61 (-0.06), THOR: 40.01 (+0.54), MKTO: 28.24 (+0.20), CRL: 73.61 (-0.33), TMH: 59.69 (-0.19), ANDE: 45.11 (+0.71), XOOM: 15.77 (+0.64), HIW: 46.66 (-0.68), PAYC: 32.37 (-0.71)
Which Biotech Stock Should Pfizer, Inc. Buy?
Motley Fool Staff, Brian Orelli, Leo Sun, and George Budwell - Motley Fool - Sun Feb 08, 7:02AM CST
Source: Pfizer. Pfizer is struggling to offset slowing sales tied to expiring patents, and that has some observers thinking that Pfizer remains on the hunt to buy another drugmaker that can spark its growth. Earlier this week, Pfizer announced...
BIIB: 391.66 (-0.45), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), CLDN: 16.45 (-0.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), SGEN: 31.57 (+0.36), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
Seattle Genetics to Present at Leerink Global Healthcare Conference
Business Wire - Thu Feb 05, 8:01AM CST
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the Leerink Global Healthcare Conference on Thursday, February 12, at 11:35 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics' website at www.seattlegenetics.com in the Investors and News section.
SGEN: 31.57 (+0.36)
Earnings Peek: Market Seems Determined To Keep Seattle Genetics In The $30s
Clinically Sound Investor - at Seeking Alpha - Mon Jan 26, 12:20PM CST
SGEN: 31.57 (+0.36)
Seattle Genetics reports February 10
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 8:45AM CST
SGEN: 31.57 (+0.36)
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2014 Financial Results on February 10, 2015
Business Wire - Wed Jan 21, 8:01AM CST
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its fourth quarter and year 2014 financial results on Tuesday, February 10, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
SGEN: 31.57 (+0.36)
ALPS Puts Twist On Biotech Investing With Medical Breakthrough ETF
Zacks Funds - Seeking Alpha - Wed Jan 14, 11:48PM CST
Health & Biotech Equities ETFs had an astounding 2014 with the NASDAQ Biotechnology index returning a stellar 34% in 2014 - emerging as the biggest winner among all the sectors. Despite overall valuation concerns in the early phase of the year,...
BBP: 28.36 (+0.12), SBIO: 27.28 (+0.14), BBC: 28.98 (+0.18), SGEN: 31.57 (+0.36), IBB: 323.46 (+3.04), RCPT: 115.83 (-0.66), NPSP: 45.88 (+0.03), XLV: 70.72 (+0.28)
Eli Lilly Inks Oncology Deals with Merck, Bristol-Myers - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 4:35PM CST
Eli Lilly and Company (LLY) has entered into separate agreements with Merck and Bristol-Myers Squibb Company to evaluate its drugs for several oncology indications.
AGN: 229.49 (+1.87), SGEN: 31.57 (+0.36), MRK: 58.81 (-0.07), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56)
Seattle Genetics, Bristol-Myers to Study Adcetris-Opdivo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 4:46PM CST
Seattle Genetics, Inc. (SGEN) and partner Bristol-Myers Squibb Company inked a deal to develop an investigational combination of Adcetris and Opdivo.
BIIB: 391.66 (-0.45), SGEN: 31.57 (+0.36), ALXN: 182.29 (+6.02), BMY: 60.04 (+0.56)
Seattle Genetics and Bristol-Myers team up in blood cancer trials
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 12:44PM CST
SGEN: 31.57 (+0.36), BMY: 60.04 (+0.56)
Bristol-Myers' stock jumps on lung-cancer drug success
By The Associated Press - AP - Mon Jan 12, 10:05AM CST
Better patient survival rates prompted Bristol-Myers Squibb to bring an early end to an advanced study of a potential treatment for one of the most common forms of lung cancer.
SGEN: 31.57 (+0.36), BMY: 60.04 (+0.56)
